Marché européen du séquençage de l’exome entier – Tendances et prévisions de l’industrie jusqu’en 2029

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché européen du séquençage de l’exome entier – Tendances et prévisions de l’industrie jusqu’en 2029

  • Medical Devices
  • Publish Reports
  • Jun 2022
  • Europe
  • 350 Pages
  • Nombre de tableaux : 152
  • Nombre de figures : 40

>Marché européen du séquençage de l'exome entier, par composant (séquençage de deuxième génération et séquençage de troisième génération), produit et service (systèmes, kits et services), application (découverte et développement de médicaments, recherche agricole et animale, diagnostic, médecine personnalisée et autres), utilisateur final (sociétés pharmaceutiques et biotechnologiques, instituts universitaires et de recherche, hôpitaux et cliniques, laboratoires cliniques et autres), canal de distribution (commerce direct, ventes au détail et autres), tendances de l'industrie et prévisions jusqu'en 2029.

Marché européen du séquençage de l'exome entier

Analyse et perspectives du marché

Le marché européen du séquençage de l'exome entier devrait connaître une croissance du marché au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 16,0 % au cours de la période de prévision de 2022 à 2029. L'augmentation de l'acceptation des méthodes de séquençage de nouvelle génération pour la prédiction, le traitement et la surveillance de diverses maladies chroniques telles que le cancer sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.

Marché du séquençage de l'exome entierCependant, les problèmes juridiques liés à la technique et aux effets secondaires associés aux traitements de séquençage de l'exome entier peuvent entraver la croissance future du marché du séquençage de l'exome entier. L'adoption d'alliances stratégiques telles que les partenariats et les acquisitions par des acteurs clés du marché constitue une opportunité pour la croissance du marché du séquençage de l'exome entier.

Rapport métrique

Détails

Période de prévision

2022 à 2029

Année de base

2021

Années historiques

2020

Unités quantitatives

Chiffre d'affaires en millions USD, prix en USD

Segments couverts

Par composant (séquençage de deuxième génération et séquençage de troisième génération), produit et service (systèmes, kits et services), application (découverte et développement de médicaments, recherche agricole et animale, diagnostic, médecine personnalisée et autres), utilisateur final (sociétés pharmaceutiques et biotechnologiques, instituts universitaires et de recherche, hôpitaux et cliniques, laboratoires cliniques et autres), canal de distribution (commerce direct, vente au détail et autres)

Pays couverts

Allemagne, France, Italie, Royaume-Uni, Espagne, Pays-Bas, Russie, Suisse, Turquie, Belgique, Reste de l'Europe

Acteurs du marché couverts

Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (une filiale de Bio-Techne), FOUNDATION MEDICINE, INC. (une filiale de F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta US Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (une filiale de PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc., entre autres.

Définition du marché du séquençage de l'exome entier

Le séquençage de l'exome entier est une technique génomique permettant de séquencer l'ensemble des régions codantes pour les protéines des gènes d'un génome. Le séquençage de l'exome entier est disponible pour les patients qui recherchent un diagnostic unifié pour plusieurs pathologies. Il s'agit d'un processus de laboratoire utilisé pour déterminer la séquence nucléotidique principalement des régions exoniques (ou codantes pour les protéines) du génome d'un individu et des séquences associées, représentant environ 1 % de la séquence d'ADN complète, également appelée WES. Le séquençage de l'exome entier est une méthode de séquençage de l'exome entier largement utilisée qui consiste à séquencer les régions codantes pour les protéines du génome. L'exome humain représente moins de 2 % du génome, mais contient environ 85 % des variantes connues liées à la maladie, ce qui fait de cette méthode une alternative rentable au séquençage du génome entier.

Le séquençage de l'exome par enrichissement de l'exome permet de détecter efficacement les variantes codantes dans un large éventail d'applications, notamment la génétique des populations, les maladies génétiques et les études sur le cancer. La croissance du marché mondial du séquençage de l'exome entier est attribuée à la réduction du temps et du coût du séquençage. Avec le développement de nouvelles technologies et de traitements contre le cancer, le marché du séquençage de l'exome entier en oncologie clinique a un énorme potentiel dans les années à venir.

Dynamique du marché du séquençage de l'exome entier en Europe

Conducteurs

  • Augmentation de l'adoption du séquençage de nouvelle génération (NGS)

Alors que la pharmacologie axée sur la génomique continue de jouer un rôle plus important dans le traitement de diverses maladies chroniques, en particulier le cancer, le séquençage de nouvelle génération (NGS) évolue en tant qu'outil puissant pour fournir un aperçu plus approfondi et plus précis des fondements moléculaires des tumeurs individuelles et des récepteurs spécifiques.

Le NGS offre des avantages en termes de précision, de sensibilité et de rapidité par rapport aux méthodes traditionnelles, qui ont le potentiel d'avoir un impact significatif dans le domaine de l'oncologie. Étant donné que le NGS peut évaluer plusieurs gènes dans un seul test, il n'est plus nécessaire de commander plusieurs tests pour identifier la mutation causale.

  • Utilisation croissante des méthodes de séquençage ciblé

Alors que la pharmacologie axée sur la génomique continue de jouer un rôle plus important dans le traitement de diverses maladies chroniques, en particulier le cancer, le séquençage de nouvelle génération (NGS) évolue en tant qu'outil puissant pour fournir un aperçu plus approfondi et plus précis des fondements moléculaires des tumeurs individuelles et des récepteurs spécifiques.

Le NGS offre des avantages en termes de précision, de sensibilité et de rapidité par rapport aux méthodes traditionnelles, qui ont le potentiel d'avoir un impact significatif dans le domaine de l'oncologie. Étant donné que le NGS peut évaluer plusieurs gènes dans un seul test, il n'est plus nécessaire de commander plusieurs tests pour identifier la mutation causale.

Retenue

  • Couverture moins complète des exons

Tous les exons ne sont pas capturés de manière exhaustive. L’exon important peut ne pas être inclus dans les annotations standard actuelles du génome humain ; et il est tout simplement difficile de couvrir 100 % de l’exome avec la technologie WES actuelle. Par conséquent, les variantes causant des maladies dans ces exons « manqués » ne sont pas détectées.

Le WES a une faible sensibilité aux variations structurelles, la détection est donc limitée. Néanmoins, certaines CNV, notamment les indels et les duplications, peuvent être détectées par WES, la limitation technique implique que d'autres sont probablement manquées

Opportunity

  • Strategic Initiatives by the key market player

The demand for whole exome sequencing is increasing in the market owing to the increased incidence of genetic disease along with increased geriatric population across the region. Thus, the top market players have implemented the strategy of collaboration with other market players aimed at improving business operations and profitability.

Challenge

  • Ethical and legal issues related to whole exome sequencing

Rapid advances in high throughput genomic technologies and next generation sequencing are making medical genomic research more readily accessible and affordable, including the sequencing of patient and control whole genomes and exomes in order to elucidate genetic factors underlying disease. Progress of high throughput genomic technologies and next generation sequencing (NGS) methods in recent years has changed the scope of human genomic studies. These advances have made it feasible to routinely perform whole exome sequencing (WES) studies.

Due to the large-scale, collaborative nature of studies, ethical and legal issues are of increasing concern and have important implications in Africa. African populations are of unique interest because, despite having the highest levels of genetic diversity, living in a vast array of environmental and cultural settings, as well as suffering from a high burden of disease that could be studied using genomics approaches, they are facing legal issues in WES.

Post COVID-19 Impact on Whole Exome Sequencing Market

COVID-19 has resulted in a substantial upsurge in demand for medical supplies from both healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the whole exome sequencing market.

Recent Development

  • In May, 2022, Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. This has helped the company to expand its presence.
  • In March, 2022, several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA seeks to educate healthcare providers and other stakeholders about the value of such testing to assure adherence to existing guidelines from professional medical societies, to inform medical management and cascade testing, and to improve clinical outcomes. This has helped company to adhere to guidelines.

Europe Whole Exome Sequencing Market Segmentation

Europe whole exome sequencing market is segmented on the basis of component, product and service, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Component

  • Second-Generation Sequencing
  • Third-Generation Sequencing

On the basis of component, the Europe whole exome sequencing market is segmented into second-generation sequencing and third-generation sequencing.

Product and Services

  • Systems
  • Kits
  • Services

On the basis of product and service, the Europe whole exome sequencing market is segmented into systems, kits and services.

Application

  • Diagnostics
  • Drug Discovery and Development
  • Personalized Medicine
  • Agriculture & Animal Research
  • Others

On the basis of application, the Europe whole exome sequencing market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.

End User

  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Clinical Laboratories
  • Others

On the basis of end user, the Europe whole exome sequencing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, clinical laboratories and others.

Distribution Channel

  • Direct Trade
  • Retail sales
  • Others

Marché du séquençage de l'exome entier

On the basis of distribution channel, the Europe whole exome sequencing market is segmented into direct trade, retail sales and others.

Whole Exome Sequencing Market Country Level Analysis

The whole exome sequencing market is analyzed and market size information is provided by component, product and service, application, end user and distribution channel.

The countries covered in the whole exome sequencing market report are Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Belgium and Rest of Europe.

Germany is expected to grow due to rapidly declining costs of sequencing, strategic alliances among major companies and research institutes.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Whole exome sequencing market also provides you with detailed market analysis for every country growth in healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, impact of regulatory scenarios, and trending parameters regarding whole exome sequencing market.

Competitive Landscape and Whole Exome Sequencing Market Share Analysis

Whole exome sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to whole exome sequencing market.

The major companies which are dealing in the  whole exome sequencing market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc., among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE WHOLE EXOME SEQUENCING (WES) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 INDUSTRIAL INSIGHTS:

4.4 CONCLUSION

5 EUROPE WHOLE EXOME SEQUENCING MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS

6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING

6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING

6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION

6.2 RESTRAINTS

6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS

6.2.2 CYBER SECURITY CONCERNS IN GENOMICS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER

6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS

6.4 CHALLENGES

6.4.1 LACK OF SKILLED PROFESSIONALS

6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING

7 EUROPE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT

7.1 OVERVIEW

7.2 SECOND-GENERATION SEQUENCING

7.2.1 SEQUENCING BY SYNTHESIS (SBS)

7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL)

7.3 THIRD-GENERATION SEQUENCING

8 EUROPE WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE

8.1 OVERVIEW

8.2 SYSTEMS

8.2.1 HISEQ SERIES

8.2.1.1 HISEQ 2500

8.2.1.2 HISEQ 1500

8.2.2 MISEQ SERIES

8.2.3 ION TORRENT PLATFORMS

8.2.3.1 ION PROTON

8.2.3.2 ION PGM

8.2.4 OTHERS

8.3 KITS

8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS

8.3.2 LIBRARY PREPARATION KITS

8.3.3 TARGET ENRICHMENT KITS

8.3.4 OTHERS

8.4 SERVICES

8.4.1 SEQUENCING SERVICES

8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES

8.4.3 OTHERS

9 EUROPE WHOLE EXOME SEQUENCING MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 DRUG DISCOVERY AND DEVELOPMENT

9.3 AGRICULTURE & ANIMAL RESEARCH

9.4 DIAGNOSTICS

9.5 PERSONALIZED MEDICINE

9.6 OTHERS

10 EUROPE WHOLE EXOME SEQUENCING MARKET, BY END USER

10.1 OVERVIEW

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.3 ACADEMIC & RESEARCH INSTITUTES

10.4 HOSPITALS AND CLINICS

10.5 CLINICAL LABORATORIES

10.6 OTHERS

11 EUROPE WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TRADE

11.3 RETAIL SALES

11.4 OTHERS

12 EUROPE WHOLE EXOME SEQUENCING MARKET, BY REGION

12.1 EUROPE

12.1.1 GERMANY

12.1.2 FRANCE

12.1.3 U.K.

12.1.4 RUSSIA

12.1.5 ITALY

12.1.6 SPAIN

12.1.7 TURKEY

12.1.8 NETHERLANDS

12.1.9 SWITZERLAND

12.1.10 BELGIUM

12.1.11 REST OF EUROPE

13 EUROPE WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: EUROPE

14 COMPANY PROFILE

14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.)

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COM PANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 MERCK KGAA

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COM PANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 EXODX (A PART OF BIO-TECHNE)

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COM PANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 THERMO FISHER SCIENTIFIC INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COM PANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COM PANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 AZENTA US, INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 PRODUCT PORTFOLIO

14.6.3 RECENT DEVELOPMENTS

14.7 BECKMAN COULTER, INC

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 BIONEER CORPORATION

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.9 CD GENOMICS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENTS

14.1 CEGAT GMBH

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 EUROFINS SCIENTIFIC

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENTS

14.12 GENEDX, LLC

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 GENEFIRST LIMITED.

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENTS

14.14 ILLUMINA, INC

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENTS

14.15 INTEGRATED DNA TECHNOLOGIES, INC.

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 MERIDIAN BIOSCIENCE, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 PSOMAGEN

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENTS

14.18 QIAGEN

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENTS

14.19 SOPHIA GENETICS

14.19.1 COMPANY SNAPSHOT

14.19.2 REVENUE ANALYSIS

14.19.3 PRODUCT PORTFOLIO

14.19.4 RECENT DEVELOPMENTS

14.2 TWIST BIOSCIENCE

14.20.1 COMPANY SNAPSHOT

14.20.2 REVENUE ANALYSIS

14.20.3 PRODUCT PORTFOLIO

14.20.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

Liste des tableaux

TABLE 1 EUROPE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 2 EUROPE SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 EUROPE SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 4 EUROPE THIRD-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 6 EUROPE SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 EUROPE SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 8 EUROPE HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 9 EUROPE ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 10 EUROPE KITS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 12 EUROPE SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 14 EUROPE WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE DRUG DISCOVERY AND DEVELOPMENT IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE AGRICULTURE & ANIMAL RESEARCH IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE DIAGNOSTICS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE PERSONALIZED MEDICINE IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 21 EUROPE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE ACADEMIC & RESEARCH INSTITUTES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE HOSPITALS AND CLINICS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 EUROPE CLINICAL LABORATORIES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 EUROPE OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 EUROPE WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 27 EUROPE DIRECT TRADE IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 EUROPE RETAIL SALES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 EUROPE OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 EUROPE WHOLE EXOME SEQUENCING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 31 EUROPE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 32 EUROPE SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 33 EUROPE WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 34 EUROPE SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 35 EUROPE HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 36 EUROPE ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 37 EUROPE KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 38 EUROPE SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 39 EUROPE WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 40 EUROPE WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 41 EUROPE WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 42 GERMANY WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 43 GERMANY SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 44 GERMANY WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 45 GERMANY SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 46 GERMANY HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 47 GERMANY ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 48 GERMANY KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 49 GERMANY SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 50 GERMANY WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 51 GERMANY WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 GERMANY WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 FRANCE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 54 FRANCE SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 55 FRANCE WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 56 FRANCE SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 57 FRANCE HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 58 FRANCE ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 59 FRANCE KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 60 FRANCE SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 61 FRANCE WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 62 FRANCE WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 63 FRANCE WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 64 U.K. WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 65 U.K. SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 66 U.K. WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 67 U.K. SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 68 U.K. HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 69 U.K. ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 70 U.K. KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 71 U.K. SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 72 U.K. WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 73 U.K. WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 74 U.K. WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 75 RUSSIA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 76 RUSSIA SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 77 RUSSIA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 78 RUSSIA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 79 RUSSIA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 80 RUSSIA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 81 RUSSIA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 82 RUSSIA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 83 RUSSIA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 84 RUSSIA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 85 RUSSIA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 86 ITALY WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 87 ITALY SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 88 ITALY WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 89 ITALY SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 90 ITALY HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 91 ITALY ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 92 ITALY KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 93 ITALY SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 94 ITALY WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 95 ITALY WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 96 ITALY WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 97 SPAIN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 98 SPAIN SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 99 SPAIN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 100 SPAIN SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 101 SPAIN HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 102 SPAIN ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 103 SPAIN KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 104 SPAIN SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 105 SPAIN WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 106 SPAIN WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 107 SPAIN WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 108 TURKEY WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 109 TURKEY SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 110 TURKEY WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 111 TURKEY SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 112 TURKEY HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 113 TURKEY ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 114 TURKEY KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 115 TURKEY SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 116 TURKEY WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 117 TURKEY WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 118 TURKEY WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 119 NETHERLANDS WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 120 NETHERLANDS SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 121 NETHERLANDS WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 122 NETHERLANDS SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 123 NETHERLANDS HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 124 NETHERLANDS ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 125 NETHERLANDS KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 126 NETHERLANDS SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 127 NETHERLANDS WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 128 NETHERLANDS WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 129 NETHERLANDS WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 130 SWITZERLAND WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 131 SWITZERLAND SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 132 SWITZERLAND WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 133 SWITZERLAND SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 134 SWITZERLAND HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 135 SWITZERLAND ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 136 SWITZERLAND KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 137 SWITZERLAND SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 138 SWITZERLAND WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 139 SWITZERLAND WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 140 SWITZERLAND WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 141 BELGIUM WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 142 BELGIUM SECOND GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

TABLE 143 BELGIUM WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 144 BELGIUM SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 145 BELGIUM HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 146 BELGIUM ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 147 BELGIUM KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 148 BELGIUM SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)

TABLE 149 BELGIUM WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 150 BELGIUM WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 151 BELGIUM WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 152 REST OF EUROPE WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)

Liste des figures

FIGURE 1 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION

FIGURE 2 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: DROC ANALYSIS

FIGURE 4 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS

FIGURE 5 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE EUROPE WHOLE EXOME SEQUENCING (WES) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASE IN USE OF WES TECHNOLOGY FOR NEW SCIENTIFIC APPLICATIONS AND INCREASING THE PREFERENCE OF WES OVER WHOLE-GENOME SEQUENCING IS ITS LOW-COST SEQUENCING CAPABILITY IS EXPECTED TO DRIVE THE EUROPE WHOLE EXOME SEQUENCING (WES) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 THE INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE WHOLE EXOME SEQUENCING (WES) MARKET IN 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE EUROPE WHOLE EXOME SEQUENCING MARKET

FIGURE 15 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2021

FIGURE 16 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2022-2029 (USD MILLION)

FIGURE 17 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, CAGR (2022-2029)

FIGURE 18 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, LIFELINE CURVE

FIGURE 19 EUROPE WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2021

FIGURE 20 EUROPE WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2022-2029 (USD MILLION)

FIGURE 21 EUROPE WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, CAGR (2022-2029)

FIGURE 22 EUROPE WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, LIFELINE CURVE

FIGURE 23 EUROPE WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2021

FIGURE 24 LOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2022-2029 (USD MILLION)

FIGURE 25 EUROPE WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 26 EUROPE WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 27 EUROPE WHOLE EXOME SEQUENCING MARKET: BY END USER, 2021

FIGURE 28 EUROPE WHOLE EXOME SEQUENCING MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 29 EUROPE WHOLE EXOME SEQUENCING MARKET: BY END USER, CAGR (2022-2029)

FIGURE 30 EUROPE WHOLE EXOME SEQUENCING MARKET: BY END USER, LIFELINE CURVE

FIGURE 31 EUROPE WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 32 EUROPE WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 33 EUROPE WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 34 EUROPE WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 35 EUROPE WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021)

FIGURE 36 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021)

FIGURE 37 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029)

FIGURE 38 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029)

FIGURE 39 EUROPE WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029)

FIGURE 40 EUROPE WHOLE EXOME SEQUENCING MARKET: COMPANY SHARE 2021 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The growth rate of the Europe whole exome sequencing market is 16.0% in the forecast period by 2029.
Component, product and service, application, end-user, and distribution channel are the factors on which the Europe whole exome sequencing market research is based.
Major companies in the Europe Whole Exome Sequencing Market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC., GeneFirst Limited, etc.
An increase in the adoption of next-generation sequencing (NGS) & growing usage of targeted sequencing methods are the growth drivers of the Europe whole exome sequencing market.
Germany dominates the Europe whole exome sequencing market due to rapidly declining costs of sequencing, and strategic alliances among major companies and research institutes.